

Ixazomib (MLN-2238)

Cat. # F1110, F1111

- Also Known as:** [(1R)-1-[[[(2S,3R)-3-hydroxy-2-[(6-phenylpyridine-2-carbonyl)amino]butanoyl]amino]-3-methylbutyl]boronic acid
- Formula:** $C_{14}H_{19}BCl_2N_2O_4$
- MW:** 361.03 Da
- CAS No.:** 1072833-77-2
- Source:** Synthetic
- Form:** Lyophilized powder
- Solubility:** > 10 mg/ml in DMSO, < 1mg/mL in water, For in vivo use, >30 mg/mL in 0.5% hydroxyethyl cellulose
- Concentration:** N/A
- Quality Assurance:** >98% by HPLC and NMR
- Description:** Ixazomib (MLN2238) (commercial name: Ninlaro[®]) is the first and only FDA-approved oral proteasome inhibitor for the treatment of multiple myeloma. It reversibly inhibits the chymotrypsin-like activity of proteasomes with IC₅₀ of 3.4 nM in cell-free assays, also inhibits the caspase-like and trypsin-like activities of proteasome with IC₅₀ of 31 and 3500 nM, respectively.
- Storage:** Eligible for room temperature shipping. Store at -80°C upon receiving; avoid multiple freeze-thaw cycles after dissolving in DMSO.
- Note:** Briefly spin the tube before removing the cap.

